Ceryvyn Therapeutics (ASX:CYV) Cash Payments: A$-272.46 Mil (TTM As of Jun. 2025)


What is Ceryvyn Therapeutics Cash Payments?

Ceryvyn Therapeutics ASX:CYV -7.69% Cash Payments is A$-272.46 Mil as of Jun. 2025. The stock has 3 warning signs investors should review.

Ceryvyn Therapeutics's Cash Payments for the six months ended in Jun. 2025 was A$-135.16 Mil.

Ceryvyn Therapeutics's Cash Payments for the trailing twelve months (TTM) ended in Jun. 2025 was A$-272.46 Mil.

Ceryvyn Therapeutics Cash Payments Historical Data

* Premium members only.

The historical data trend for Ceryvyn Therapeutics's Cash Payments can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ceryvyn Therapeutics Cash Payments Chart

Ceryvyn Therapeutics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Cash Payments
Get a 7-Day Free Trial Premium Member Only Premium Member Only -67.88 -109.66 -194.14 -256.86 -268.72

Ceryvyn Therapeutics Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
Cash Payments Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -89.33 -115.37 -140.57 -137.30 -135.16

Ceryvyn Therapeutics Cash Payments Calculation

A company's cash flow from operations for a time period can be determined using either the direct or indirect method. The indirect method modifies the operating section from accrual accounting to a cash basis by taking the net income generated in a period and adding or subtracting changes in the asset and liability accounts to determine the implied cash flow. However, the direct method uses actual cash inflows and outflows from the company's operations directly. Cash Payments represents cash flow paid from operating activities in the direct cash flow method.

GuruFocus lists following items in "Cash Payments" section for non-financial companies:
Payments to Suppliers for Goods and Services
Payments on Behalf of Employees
Other Cash Payments from Operating Activities

Cash Payments for the trailing twelve months (TTM) ended in Jun. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-272.46 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Cash Payments →
What does a Cash Payments of A$-272.46 Mil mean?
Ceryvyn Therapeutics (ASX:CYV) has a Cash Payments of A$-272.46 Mil as of Jun. 2025. Cash Payments represents cash paid from operating activities in direct cash flow method. View historical data for Ceryvyn Therapeutics and its competitors.
Is Ceryvyn Therapeutics' Cash Payments too high?
Ceryvyn Therapeutics' current Cash Payments is A$-272.46 Mil.
How does Ceryvyn Therapeutics' Cash Payments compare to VRTX and REGN?
Ceryvyn Therapeutics' Cash Payments of A$-272.46 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Payments for a Biotechnology company?
A good Cash Payments depends on the Biotechnology industry context. However, Cash Payments should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Payments mean?
A high Cash Payments can signal that a stock is expensive relative to its fundamentals. Cash Payments represents cash paid from operating activities in direct cash flow method. View historical data for Ceryvyn Therapeutics and its competitors. Ceryvyn Therapeutics's current Cash Payments is A$-272.46 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ceryvyn Therapeutics stock overvalued right now?
Ceryvyn Therapeutics (ASX:CYV) has a current Cash Payments of A$-272.46 Mil. The current Cash Payments is A$-272.46 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Payments calculated?
Cash Payments is calculated from a company's financial statements. For Ceryvyn Therapeutics (ASX:CYV), the current Cash Payments is A$-272.46 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Ceryvyn Therapeutics Business Description

Address C/ Prime Company Compliance, 505 Little Collins Street, Level 9, Melbourne, VIC, AUS, 3000
Opthea Ltd is engaged in researching and developing novel therapeutic products that target Vascular Endothelial Growth Factors (VEGF) C, D, and R3. The Group operates in one industry and two geographical areas, namely biotechnology and healthcare, with operations in Australia and the United States. The company focuses on developing biological therapeutics for eye diseases and is currently developing a novel biologic therapy, OPT-302, for the treatment of eye conditions. Its products are based on an intellectual property portfolio covering VEGF-C, VEGF-D, and VEGF Receptor-3 targets, aimed at treating diseases associated with blood and lymphatic vessel growth and vascular leakage.